Page last updated: 2024-10-29

isradipine and Amyotrophic Lateral Sclerosis

isradipine has been researched along with Amyotrophic Lateral Sclerosis in 1 studies

Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arsac, C1
Raymond, C1
Martin-Moutot, N1
Dargent, B1
Couraud, F1
Pouget, J1
Seagar, M1

Other Studies

1 other study available for isradipine and Amyotrophic Lateral Sclerosis

ArticleYear
Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum.
    Annals of neurology, 1996, Volume: 40, Issue:5

    Topics: Amyotrophic Lateral Sclerosis; Animals; Autoantibodies; Brain; Calcium Channel Blockers; Calcium Cha

1996